Why tocilizumab could be an effective treatment for severe COVID-19?
Identifieur interne : 000062 ( 2020/Analysis ); précédent : 000061; suivant : 000063Why tocilizumab could be an effective treatment for severe COVID-19?
Auteurs : Binqing Fu [République populaire de Chine] ; Xiaoling Xu [République populaire de Chine] ; Haiming Wei [République populaire de Chine]Source :
- Journal of translational medicine [ 1479-5876 ] ; 2020.
Descripteurs français
- KwdFr :
- Anticorps monoclonaux humanisés (usage thérapeutique), Humains, Indice de gravité médicale, Infections à coronavirus (immunologie), Infections à coronavirus (traitement médicamenteux), Interleukine-6 (antagonistes et inhibiteurs), Pandémies, Pneumopathie virale (immunologie), Pneumopathie virale (traitement médicamenteux).
- MESH :
- antagonistes et inhibiteurs : Interleukine-6.
- immunologie : Infections à coronavirus, Pneumopathie virale.
- traitement médicamenteux : Infections à coronavirus, Pneumopathie virale.
- usage thérapeutique : Anticorps monoclonaux humanisés.
- Humains, Indice de gravité médicale, Pandémies.
English descriptors
- KwdEn :
- MESH :
- chemical , antagonists & inhibitors : Interleukin-6.
- chemical , therapeutic use : Antibodies, Monoclonal, Humanized.
- drug therapy : Coronavirus Infections, Pneumonia, Viral.
- immunology : Coronavirus Infections, Pneumonia, Viral.
- Betacoronavirus, Humans, Pandemics, Severity of Illness Index.
Abstract
A severe pneumonia-associated respiratory syndrome caused by a new coronavirus was identified in December 2019 (COVID-19), spread rapidly and has become a world-wide public health challenge. About 25% of COVID-19 patients experienced severe complications including acute respiratory distress syndrome (ARDS), and even progressed into an intensive care unit (ICU) admission and died. The exploration for the mortality causes and advancing novel therapeutic development of severe COVID-19 is crucial at the moment. The biopsy samples analysis at autopsy suggested that increased alveolar exudate caused by aberrant host immune response and inflammatory cytokine storm probably impedes alveolar gas exchange and contributes to the high mortality of severe COVID-19 patients. Our research has identified that pathogenic T cells and inflammatory monocytes incite inflammatory storm with large amount of interleukin 6, therefore monoclonal antibody that targets the IL-6 pathways may potentially curb inflammatory storm. Moreover, Tocilizumab treatment that blocking IL-6 receptors showed inspiring clinical results including temperature returned to normal quickly and respiratory function improved. Therefore, we suggest that Tocilizumab is an effective treatment in severe patients of COVID-19 to calm the inflammatory storm and reduce mortality.
DOI: 10.1186/s12967-020-02339-3
PubMed: 32290839
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 000156
- to stream PubMed, to step Curation: 000156
- to stream PubMed, to step Checkpoint: 000047
- to stream Ncbi, to step Merge: 003A30
- to stream Ncbi, to step Curation: 003A30
- to stream Ncbi, to step Checkpoint: 003A30
- to stream Main, to step Merge: 000062
- to stream Main, to step Curation: 000062
- to stream Main, to step Exploration: 000062
- to stream 2020, to step Extraction: 000062
Links to Exploration step
pubmed:32290839Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Why tocilizumab could be an effective treatment for severe COVID-19?</title><author><name sortKey="Fu, Binqing" sort="Fu, Binqing" uniqKey="Fu B" first="Binqing" last="Fu">Binqing Fu</name><affiliation wicri:level="1"><nlm:affiliation>Institute of Immunology and the CAS Key Laboratory of Innate Immunity and Chronic Disease, School of Life Science and Medical Center, University of Science and Technology of China, Hefei, Anhui, 230001, China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Institute of Immunology and the CAS Key Laboratory of Innate Immunity and Chronic Disease, School of Life Science and Medical Center, University of Science and Technology of China, Hefei, Anhui, 230001</wicri:regionArea><wicri:noRegion>230001</wicri:noRegion></affiliation></author><author><name sortKey="Xu, Xiaoling" sort="Xu, Xiaoling" uniqKey="Xu X" first="Xiaoling" last="Xu">Xiaoling Xu</name><affiliation wicri:level="1"><nlm:affiliation>The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, 230001, China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, 230001</wicri:regionArea><wicri:noRegion>230001</wicri:noRegion></affiliation></author><author><name sortKey="Wei, Haiming" sort="Wei, Haiming" uniqKey="Wei H" first="Haiming" last="Wei">Haiming Wei</name><affiliation wicri:level="1"><nlm:affiliation>Institute of Immunology and the CAS Key Laboratory of Innate Immunity and Chronic Disease, School of Life Science and Medical Center, University of Science and Technology of China, Hefei, Anhui, 230001, China. ustcwhm@ustc.edu.cn.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Institute of Immunology and the CAS Key Laboratory of Innate Immunity and Chronic Disease, School of Life Science and Medical Center, University of Science and Technology of China, Hefei, Anhui, 230001</wicri:regionArea><wicri:noRegion>230001</wicri:noRegion></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2020">2020</date><idno type="RBID">pubmed:32290839</idno><idno type="pmid">32290839</idno><idno type="doi">10.1186/s12967-020-02339-3</idno><idno type="wicri:Area/PubMed/Corpus">000156</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000156</idno><idno type="wicri:Area/PubMed/Curation">000156</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000156</idno><idno type="wicri:Area/PubMed/Checkpoint">000047</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000047</idno><idno type="wicri:Area/Ncbi/Merge">003A30</idno><idno type="wicri:Area/Ncbi/Curation">003A30</idno><idno type="wicri:Area/Ncbi/Checkpoint">003A30</idno><idno type="wicri:Area/Main/Merge">000062</idno><idno type="wicri:Area/Main/Curation">000062</idno><idno type="wicri:Area/Main/Exploration">000062</idno><idno type="wicri:Area/2020/Extraction">000062</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Why tocilizumab could be an effective treatment for severe COVID-19?</title><author><name sortKey="Fu, Binqing" sort="Fu, Binqing" uniqKey="Fu B" first="Binqing" last="Fu">Binqing Fu</name><affiliation wicri:level="1"><nlm:affiliation>Institute of Immunology and the CAS Key Laboratory of Innate Immunity and Chronic Disease, School of Life Science and Medical Center, University of Science and Technology of China, Hefei, Anhui, 230001, China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Institute of Immunology and the CAS Key Laboratory of Innate Immunity and Chronic Disease, School of Life Science and Medical Center, University of Science and Technology of China, Hefei, Anhui, 230001</wicri:regionArea><wicri:noRegion>230001</wicri:noRegion></affiliation></author><author><name sortKey="Xu, Xiaoling" sort="Xu, Xiaoling" uniqKey="Xu X" first="Xiaoling" last="Xu">Xiaoling Xu</name><affiliation wicri:level="1"><nlm:affiliation>The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, 230001, China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, 230001</wicri:regionArea><wicri:noRegion>230001</wicri:noRegion></affiliation></author><author><name sortKey="Wei, Haiming" sort="Wei, Haiming" uniqKey="Wei H" first="Haiming" last="Wei">Haiming Wei</name><affiliation wicri:level="1"><nlm:affiliation>Institute of Immunology and the CAS Key Laboratory of Innate Immunity and Chronic Disease, School of Life Science and Medical Center, University of Science and Technology of China, Hefei, Anhui, 230001, China. ustcwhm@ustc.edu.cn.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Institute of Immunology and the CAS Key Laboratory of Innate Immunity and Chronic Disease, School of Life Science and Medical Center, University of Science and Technology of China, Hefei, Anhui, 230001</wicri:regionArea><wicri:noRegion>230001</wicri:noRegion></affiliation></author></analytic><series><title level="j">Journal of translational medicine</title><idno type="eISSN">1479-5876</idno><imprint><date when="2020" type="published">2020</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antibodies, Monoclonal, Humanized (therapeutic use)</term><term>Betacoronavirus</term><term>Coronavirus Infections (drug therapy)</term><term>Coronavirus Infections (immunology)</term><term>Humans</term><term>Interleukin-6 (antagonists & inhibitors)</term><term>Pandemics</term><term>Pneumonia, Viral (drug therapy)</term><term>Pneumonia, Viral (immunology)</term><term>Severity of Illness Index</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Anticorps monoclonaux humanisés (usage thérapeutique)</term><term>Humains</term><term>Indice de gravité médicale</term><term>Infections à coronavirus (immunologie)</term><term>Infections à coronavirus (traitement médicamenteux)</term><term>Interleukine-6 (antagonistes et inhibiteurs)</term><term>Pandémies</term><term>Pneumopathie virale (immunologie)</term><term>Pneumopathie virale (traitement médicamenteux)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="antagonists & inhibitors" xml:lang="en"><term>Interleukin-6</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antibodies, Monoclonal, Humanized</term></keywords><keywords scheme="MESH" qualifier="antagonistes et inhibiteurs" xml:lang="fr"><term>Interleukine-6</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Coronavirus Infections</term><term>Pneumonia, Viral</term></keywords><keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Infections à coronavirus</term><term>Pneumopathie virale</term></keywords><keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Coronavirus Infections</term><term>Pneumonia, Viral</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Infections à coronavirus</term><term>Pneumopathie virale</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Anticorps monoclonaux humanisés</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Betacoronavirus</term><term>Humans</term><term>Pandemics</term><term>Severity of Illness Index</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Humains</term><term>Indice de gravité médicale</term><term>Pandémies</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">A severe pneumonia-associated respiratory syndrome caused by a new coronavirus was identified in December 2019 (COVID-19), spread rapidly and has become a world-wide public health challenge. About 25% of COVID-19 patients experienced severe complications including acute respiratory distress syndrome (ARDS), and even progressed into an intensive care unit (ICU) admission and died. The exploration for the mortality causes and advancing novel therapeutic development of severe COVID-19 is crucial at the moment. The biopsy samples analysis at autopsy suggested that increased alveolar exudate caused by aberrant host immune response and inflammatory cytokine storm probably impedes alveolar gas exchange and contributes to the high mortality of severe COVID-19 patients. Our research has identified that pathogenic T cells and inflammatory monocytes incite inflammatory storm with large amount of interleukin 6, therefore monoclonal antibody that targets the IL-6 pathways may potentially curb inflammatory storm. Moreover, Tocilizumab treatment that blocking IL-6 receptors showed inspiring clinical results including temperature returned to normal quickly and respiratory function improved. Therefore, we suggest that Tocilizumab is an effective treatment in severe patients of COVID-19 to calm the inflammatory storm and reduce mortality.</div></front></TEI><affiliations><list><country><li>République populaire de Chine</li></country></list><tree><country name="République populaire de Chine"><noRegion><name sortKey="Fu, Binqing" sort="Fu, Binqing" uniqKey="Fu B" first="Binqing" last="Fu">Binqing Fu</name></noRegion><name sortKey="Wei, Haiming" sort="Wei, Haiming" uniqKey="Wei H" first="Haiming" last="Wei">Haiming Wei</name><name sortKey="Xu, Xiaoling" sort="Xu, Xiaoling" uniqKey="Xu X" first="Xiaoling" last="Xu">Xiaoling Xu</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/2020/Analysis
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000062 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/2020/Analysis/biblio.hfd -nk 000062 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= SrasV1
|flux= 2020
|étape= Analysis
|type= RBID
|clé= pubmed:32290839
|texte= Why tocilizumab could be an effective treatment for severe COVID-19?
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/2020/Analysis/RBID.i -Sk "pubmed:32290839" \
| HfdSelect -Kh $EXPLOR_AREA/Data/2020/Analysis/biblio.hfd \
| NlmPubMed2Wicri -a SrasV1
| This area was generated with Dilib version V0.6.33. |  |